SCHEMBL22324948

SCHEMBL22324948

O=C1CCCN1Cc1ccc(C2CCNCC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.52
HRH3 Q9Y5N1 1/20 0.49
HTR2C P28335 1/20 0.45
HTR2B P41595 1/20 0.45
ACACB O00763 1/20 0.45
LTA4H P09960 1/20 0.45
GRIA2 P42262 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
PLAT P00750 1/20 0.42
TP53 P04637 1/20 0.42
ACHE P22303 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
CDC7 O00311 1/20 0.41
PLK4 O00444 1/20 0.41
AURKA O14965 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22324823 0.82 ALDH1A1 (0.44) L3MBTL1HRH3HTR2CHTR2BPLAT
SCHEMBL11200681 0.80 L3MBTL1 (0.76) L3MBTL1HRH3ACACBLTA4HGRIA2
SCHEMBL22324880 0.80 CYP1A2 (0.46) HRH3GRIA2CYP1A2CYP2C9PLAT
SCHEMBL22324855 0.80 L3MBTL1 (0.43) L3MBTL1HRH3ACACBGRIA2CYP1A2
SCHEMBL22119515 0.80 DDB1 (0.58) HTR2CHTR2BTP53
SCHEMBL22324924 0.77 L3MBTL1 (0.43) L3MBTL1HRH3ACACBLTA4HGRIA2
SCHEMBL22324765 0.76 L3MBTL1 (0.42) L3MBTL1HRH3ACACBLTA4HGRIA2
SCHEMBL6109530 0.76 SLC6A2 (0.46) L3MBTL1HTR2CPLATACHECHRM2
SCHEMBL7674995 0.75 SMN1; SMN2 (0.54) HRH3TP53PARP1SMN1; SMN2
SCHEMBL6109813 0.75 ACHE (0.49) L3MBTL1HRH3HTR2CACHESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479816-B2 20-HETE formation inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 US disclosed
US-20220144797-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-12 US disclosed
US-20220144797-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-12 US disclosed
WO-2020163689-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-08-13 WO disclosed
WO-2020163689-A1 20-HETE FORMATION INHIBITORS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144797-A1 20-HETE FORMATION INHIBITORS CYP4A22, ALOX5, ALOX15 L3MBTL1 4595/4885HRH3 2749/4885HTR2C 235/4885
US-12479816-B2 20-HETE formation inhibitors CYP4A22, ALOX5, ALOX15 L3MBTL1 4595/4885HRH3 2749/4885HTR2C 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.